Integra LifeSciences Holdings (IART)

Price$15.67

Value ScoreC

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)29.23%

Price vs S&P 500 (4W)41.51%

VGM Score52.56

Market Capitalization$1.24B

All Metrics

P/CF (Annual)24.54x

Book Value / Share (Quarterly)$13.40

P/TBV (Annual)5.18x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)1.63%

Cash Flow / Share (Quarterly)$-0.13

Price vs S&P 500 (YTD)18.21%

Gross Margin (TTM)57.08%

Net Profit Margin (TTM)-30.15%

EPS (TTM)$-6.46

10-Day Avg Trading Volume0.99M

EPS Excl Extra (TTM)$-6.46

Revenue Growth (5Y)3.57%

EPS (Annual)$-6.74

ROI (Annual)-17.81%

Gross Margin (Annual)56.62%

Net Profit Margin (5Y Avg)-1.01%

Cash / Share (Quarterly)$3.41

Revenue Growth QoQ (YoY)2.42%

ROA (Last FY)-14.34%

Revenue Growth TTM (YoY)1.24%

EBITD / Share (TTM)$-5.88

ROE (5Y Avg)-5.13%

Operating Margin (TTM)-28.37%

Cash Flow / Share (Annual)$-0.58

P/B Ratio1.19x

P/B Ratio (Quarterly)0.70x

Net Income / Employee (Annual)$-116,700

EV / Revenue (TTM)1.74x

Net Interest Coverage (TTM)-7.31x

ROA (TTM)-13.68%

EV / EBITDA (TTM)124.43x

EPS Incl Extra (Annual)$-6.74

Current Ratio (Annual)2.54x

Quick Ratio (Quarterly)1.67x

3-Month Avg Trading Volume0.91M

52-Week Price Return26.50%

EV / Free Cash Flow (Annual)16.19x

Revenue / Employee (TTM)$371,500

Tangible BV / Share (Quarterly)$4.33

P/S Ratio (Annual)0.76x

Asset Turnover (Annual)0.45x

52-Week High$16.70

Operating Margin (5Y Avg)1.78%

EPS Excl Extra (Annual)$-6.74

CapEx CAGR (5Y)8.40%

Tangible BV CAGR (5Y)-2.59%

26-Week Price Return45.16%

Quick Ratio (Annual)1.25x

13-Week Price Return41.57%

Total Debt / Equity (Annual)1.78x

Current Ratio (Quarterly)3.38x

Enterprise Value$2.86B

Revenue / Share Growth (5Y)5.78%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)-5.70%

Revenue / Employee (Annual)$369,400

Inventory Turnover (Annual)1.54x

Pretax Margin (Annual)-34.46%

Cash / Share (Annual)$3.39

3-Month Return Std Dev70.77%

Gross Margin (5Y Avg)61.07%

Net Income / Employee (TTM)$-112,000

EBITDA CAGR (5Y)-17.88%

EBITDA Interim CAGR (5Y)-28.39%

ROE (Last FY)-49.50%

Net Interest Coverage (Annual)-6.47x

EPS Basic Excl Extra (Annual)$-6.74

P/FCF (TTM)33.47x

Receivables Turnover (TTM)6.36x

EV / Free Cash Flow (TTM)26.03x

Total Debt / Equity (Quarterly)1.79x

EPS Incl Extra (TTM)$-6.46

Receivables Turnover (Annual)5.93x

ROI (TTM)-17.16%

P/S Ratio (TTM)0.75x

Pretax Margin (5Y Avg)-0.54%

Revenue / Share (Annual)$21.33

Tangible BV / Share (Annual)$4.38

Forward P/E6.37x

Free OCF CAGR (5Y)-31.13%

Price vs S&P 500 (52W)-1.71%

Year-to-Date Return29.15%

5-Day Price Return6.23%

EPS Normalized (Annual)$-6.74

ROA (5Y Avg)-0.72%

Net Profit Margin (Annual)-31.58%

Month-to-Date Return52.18%

Cash Flow / Share (TTM)$2.73

EBITD / Share (Annual)$-6.26

Operating Margin (Annual)-30.25%

LT Debt / Equity (Annual)1.66x

P/CF (TTM)17.30x

ROI (5Y Avg)-1.01%

LT Debt / Equity (Quarterly)1.75x

EPS Basic Excl Extra (TTM)$-6.46

P/TBV (Quarterly)5.05x

P/B Ratio (Annual)0.93x

Inventory Turnover (TTM)1.50x

Pretax Margin (TTM)-32.59%

Book Value / Share (Annual)$13.40

Price vs S&P 500 (13W)31.82%

Beta1.26x

P/FCF (Annual)82.35x

Revenue / Share (TTM)$21.37

ROE (TTM)-47.65%

52-Week Low$8.70

vGradeC

gGradeD

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.54est. 0.41

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

2.71

2.75

2.63

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
IARTIntegra LifeSciences Holdings	C	D	B	$15.67
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

Integra Lifesciences Holdings Corp is a New Jersey-based medical devices company specializing in regenerative therapy, extremity orthopedics, and neurosurgical solutions. The company operates through two main segments—Codman Specialty Surgical, which generates the majority of revenue, and Tissue Technologies—with a global presence spanning North America, Europe, and Asia Pacific, supported by substantial U.S. market sales.